Conditions: Pulmonary Disease, Chronic Obstructive
Keywords: Chronic Bronchitis Anticholinergic Emphysema Long-acting muscarinic antagonist COPD
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 285
Healthy volunteers: no

Brief summary:
The study will evaluate the efficacy, safety, and pharmacokinetics of GSK573719 compared with placebo in subjects with COPD

Detailed description:
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate 3 doses of GSK573719 administered once-daily over 28 days in subjects with COPD.

Arms:
arm 1: 125mcg once-daily via novel dry powder inhaler arm 2: 250mcg once-daily via novel dry powder inhaler arm 3: 500mcg once-daily via novel dry powder inhaler arm 4: once-daily via novel dry powder inhaler

Interventions: intervention 1: GSK573719 125mcg intervention 2: GSK573719 250mcg intervention 3: GSK573719 500mcg intervention 4: Placebo
Intervention descriptions: intervention 1: 125mcg once-daily intervention 2: 250mcg once-daily intervention 3: 500mcg once-daily intervention 4: once-daily

Protocol document: